anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening neurosurgical emergency with a high mortality rate. Delayed cerebral ischemia (DCI) and cerebral vasospasm (CVS) are delayed products of early brain injury (EBI), which may constitute the principal determinant of an unfavorable patient prognosis. Consequently, the mitigation of DCI and CVS assumes paramount significance in the pursuit of enhanced patient outcomes. However, except for oral nimodipine, there is no effective therapy available in the current guideline. Hence, the exigency arises to proffer novel treatment paradigms. The diversity of hydrogen therapeutic targets has been largely reported in basic research, unveiling its latent capacity to ameliorate EBI in aSAH patients.
METHODS: Early Hydrogen-Oxygen Gas Mixture Inhalation in Patients with Aneurysmal Subarachnoid Hemorrhage (HOMA), a single-center, prospective, open-labeled, randomized controlled clinical trial, endeavors to evaluate the efficacy and safety of hydrogen-oxygen gas mixture inhalation therapy in aSAH patients. A cohort of 206 patients will be randomized to either hydrogen-oxygen gas mixture inhalation group (8 h per day, 3 L/min, hydrogen concentration of 67%, oxygen concentration of 33%) or oxygen inhalation group (8 h per day, 3 L/min, oxygen concentration of 33%) within 72 h after aSAH and treated for 7 days in the ICU ward. The primary outcomes are the incidence of DCI and CVS during hospitalization.
DISCUSSION: The HOMA aims to evaluate the effectiveness of hydrogen-oxygen gas mixture inhalation therapy in preventing DCI or CVS and improving outcomes in aSAH patients. Notably, this is the first large-scale trial of hydrogen therapy in aSAH patients. Given that the Chinese population represents a significant portion of the global population and the increasing incidence of stroke due to aging, optimizing patient care is vital. Given the current challenges in aSAH patient outcomes, initiating more prospective clinical trials is essential. Recent research has shown hydrogen's therapeutic potential, aligning with EBI in aSAH, driving our exploration of hydrogen therapy's mechanisms in post-aneurysm rupture damage.
ETHICS AND DISSEMINATION: The protocol for the HOMA study was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (KY 2022-020-02). All results of the present study will be published in peer-reviewed journals and presented at relevant conferences.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05282836. Registered on March 16, 2022.
The safety and effectiveness of XALKORI have been established in pediatric patients 1 year of age and older with relapsed or refractory, systemic ALK-positive ALCL or with unresectable, recurrent, or refractory ALK-positive IMT [see Adverse Reactions (6.1), Clinical Studies (14.2, 14.3)]. The safety and effectiveness have not been established in pediatric patients younger than 1 year of age with ALCL or with IMT, or in any pediatric patients with NSCLC.

In a study that evaluated XALKORI in combination with chemotherapy in pediatric patients with newly diagnosed ALCL (Study ANHL12P1; NCT01979536), 13 of 66 (20%) patients had a Grade 2 or higher thromboembolic event, including pulmonary embolism in 6%. The safety and effectiveness of XALKORI in combination with chemotherapy have not been established in patients with newly diagnosed ALCL.

Juvenile Animal Toxicity Data

Decreased bone formation in growing long bones was observed in immature rats at 150 mg/kg/day following once daily dosing for 28 days (approximately 5.4 times the recommended human dose based on AUC). Other toxicities of potential concern to pediatric patients have not been evaluated in juvenile animals.
The invention belongs to the field of traditional Chinese medicines, and particularly relates to application of herba dendrobii extractives for preparing a medicine capable of treating xerophthalmia. The invention also relates to a medicine used for treating the xerophthalmia. The herba dendrobii extractives can be applied in the medicine capable of treating the xerophthalmia. The medicine used for treating the xerophthalmia takes the herba dendrobii extractives as effective ingredients and comprises pharmaceutically acceptable carriers or auxiliary materials. The medicine can be prepared into any pharmaceutical dosage forms including injection preparation, oral preparation, mist spray preparation, ointment preparation, guttae ophthalmicae, patch and the like according to a common method for medicine preparation. According to the herba dendrobii extractives provided by the invention, the breakup time of a tear film is prolonged, and corneal injury is repaired so as to achieve a purpose on treating and preventing the xerophthalmia.
FIELD: medicine. SUBSTANCE: preparation has an active agent - microbial mass of living bifidobacteria taken at effective amount and pharmaceutically acceptable additions. Preferable amount of bifidobacteria is 10 3 -10 8  living cells per one dose. Bifidobacteria that can be used: strains Bifidobacterium bifidum N 1, N 791 or "ЛБА"-3. Additionally, agent can contain one or some biologically active components showing immunomodulating, regenerating or protective action at amount 0.1-100.0 mg per one dose. Other additional biologically active components can be: hyaluronic acid, lysozyme, interferons, antiviral and antimycotic substances. The special additions can be: confectionery, food or friture fat, butyrum-cacao, paraffin, Vaseline, lanolin and emulsifier taken at amount 1.5-2.2 g per one dose. Preparation can be made as suppository, ointment or cream. Method of prophylaxis and treatment of urogenital infections involves intravaginal and/or rectal administration to patient of medicinal preparation containing 10 3 -10 8  living cells of bifidobacteria per one dose for 10-30 days; for prophylaxis - 1-2 doses and for treatment - 2 doses per a day. Before, simultaneously or after administration of preparation antibacterial, antimycotic or eubiotic agents can be administrated also. EFFECT: enhanced effectiveness of preparation. 9 cl, 13 tbl
INTRODUCTION: Etranacogene dezaparvovec (EDZ), Hemgenix, is a gene therapy recently approved for people with hemophilia B (PwHB).
OBJECTIVE: To estimate long-term clinical impact and cost of EDZ in the United States (US).
METHODS: A decision-analytic model was developed to evaluate the long-term impact of introducing EDZ for PwHB over a 20-year time horizon. Factor IX (FIX) prophylaxis comparator was a weighted average of different FIX prophylaxis regimens based on US market share data. We compared a scenario in which EDZ is introduced in the US versus a scenario without EDZ. Clinical inputs (annualized FIX-treated bleed rate; adverse event rates) were obtained from HOPE-B phase 3 trial. EDZ durability input was sourced from an analysis predicting long-term FIX activity with EDZ. EDZ one-time price was assumed at $3.5 million. Other medical costs, including FIX prophylaxis, disease monitoring, bleed management, and adverse events were from literature. The model estimated annual and cumulative costs, treated bleeds, and joint procedures over 20 years from EDZ introduction.
RESULTS: Approximately 596 PwHB were eligible for EDZ. EDZ uptake was estimated to avert 11,282 bleeds and 64 joint procedures over 20 years. Although adopting EDZ resulted in an annual excess cost over years 1-5 (mean: $53 million annually, total $265 million), annual cost savings were achieved beginning in year 6 (mean: $172 million annually; total $2.58 billion in years 6-20). The total cumulative 20-year cost savings was $2.32 billion, with cumulative cost savings beginning in year 8.
CONCLUSION: Introducing EDZ to treat PwHB is expected to result in cost savings and patient benefit over 20 years. Initiating PwHB on EDZ sooner can produce greater and earlier savings and additional bleeds avoided. These results may be a conservative estimate of the full value of EDZ, as PwHB would continue to accrue savings beyond 20 years.
A data processor maintains an electronic exercise program, which defines exercise sessions defining exercise sets for a subject on one or more exercise apparatuses. The data processor makes a selection ( 306 ) between an exercise set ( 320 ) and a performance test ( 308 ). If a set is selected, instructions relating to the set are given. Each repetition is detected, a risk of injury is assessed, and if a threshold is exceeded, instructions for reducing likelihood for injury are given. Repetitions are counted until detection of a last repetition in the set ( 410 ). Feedback is given after the last repetition. If a performance test ( 308 ) is selected, instructions relating to the test are given. Subject's performance is monitored until termination of the test. After the test, the exercise program ( 310 ) is adapted based on the monitored performance data.
The present invention relates to a fingernail or toenail care composition and to a nail or toenail care method using same. The fingernail or toenail care composition of the present invention comprises, as active ingredients, phytoncide essential oil and rosin extracted from nut pines, pines, firs or Japanese cypress. In addition, the fingernail or toenail care method of the present invention involves applying the fingernail or toenail care composition of the present invention to the surface of the fingernail or toenail of a user prior to the application of a fingernail or toenail polish, in order to form a protective coating. The fingernail or toenail care composition according to the present invention comprises, as active ingredients, phytoncide essential oil and rosin which are not harmful to the human body. Therefore, the composition of the present invention easily forms a protective coating when applied to the surface of the fingernails or toenails, and blocks harmful substances generated by the fingernail- or toenail-coloring polish and thus effectively protects the fingernails or toenails. The composition of the present invention removes the offensive odors of the coloring polish, and further changes the offensive odors into a natural pine odor to provide users with comfort. Further, the composition of the present invention, in which the content of the phytoncide essential oil and rosin are appropriately adjusted, has superior applicability, drying properties, and adhesiveness, and the coloring polish including the composition of the present invention quickly dries to provide user convenience.
Uric acid plays a role not only in the pathogenesis of gout but is also a predictor of cardiovascular disease, hypertension and renal disease in man. We have identified the human urate ion channel transporter (hUAT), located in the proximal convoluted tubule of the kidney that is involved in both the secretion and reabsorption of urate across the tubule. This channel has a unique lectin binding site that in in-vitro studies, has been found to be modulated by glucose, galactose and lactose. We have also identified a mutation (G/A polymorphism) in our laboratory, that in in-vitro studies has demonstrated diminished hUAT channel activity. Cross-sectional studies have earlier shown that uric acid levels vary with serum glucose levels. Studies have also reported that a low-fat dairy diet reduces the incidence of gout, while others have shown that this diet reduces blood pressure significantly when compared with a non-dairy diet. We hypothesize that the effect of blood glucose levels in lowering uric acid levels is through the regulation of hUAT channel activity. We also hypothesize that a low-fat dairy diet reduces serum uric acid levels through hUAT regulation leading to a decrease in the incidence of gout and a reduction in blood pressure levels. In our proposed randomized, controlled, cross-over trial in healthy adult volunteers, we aim to study the effect of a low-fat dairy diet and a non-dairy diet on serum uric acid levels, the renal fractional excretion of uric acid and blood pressure. We will also study the effect of an acute intravenous infusion of glucose on these parameters. DNA analysis for hUAT mutations of study subjects will be done to assess if there is a blunted response of hUAT activity in subjects with the polymorphism as compared to normal individuals.
Patients diagnosed with metastatic renal cell carcinoma undergo collection of samples prior to baseline and then after 4 months of systemic treatment for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI after completion of 4 months of systemic treatment.
The methods of the present invention are useful for determining whether an individual has or is at risk of developing a neuroimmune-based psychiatric disorder by detecting the expression level of one or more cytokine receptors in a biological sample. The methods of the present invention are also useful for the  in vivo  imaging of brain tissue by detecting one or more imaging agents such as ligands  (e.g. , cytokines) that bind to one or more cytokine receptors. In addition, the methods of the present invention are useful for identifying compounds that modulate ( e.g. , increase) the expression level or activity of one or more cytokine receptors. The present invention further provides therapeutic methods that target one or more cytokine receptors for the treatment of a neuroimmune-based psychiatric disorder.
Synthetic polypeptide (I) having an aminoacid residue sequence corresp. to a sequence of a determinant domain of an oncoprotein encoded by an oncogenic virus. The determinant domain is vicinal to, but exclusive of, an active site of the oncoprotein. - (I) has the capacity, alone or as a conjugate bound to a carrier, of inducing prodn. of antibodies when injected in a host. The antibodies inhibit a reaction at the active site of the oncoprotein. Antibody raised to (I) is also new.
FIELD: production of cosmetic goods. SUBSTANCE: tone cream is designed for skin make-up. Tone cream contains fat phase, texturizing emulsifiers, fillers, conserving agents, perfume composition, water, and, additionally, moisturizing agent and nutrient additives. Said cream possesses light consistency and higher applying ability, masking minor skin defects. It does not prevent dermal respiration, and actively moisturizes and nourishes skin. EFFECT: improved quality. 8 cl, 2 tbl
Across the US, substance use (SU) is a significant public health concern, with an estimated 11.1 million misusing prescription opioids. Rates of opioid use disorders (OUDs) have increased exponentially, with 60% of overdoses attributed to heroin and illicit synthetics (such as Fentanyl). Although opioid use among youth is low compared to adults, experimentation and regular use increases later in adolescence as youth transition to adulthood. Juvenile justice (JJ)-involved youth represent a particularly vulnerable population, as they often experience mental health disorders, dysfunctional family/social relationships, and complex trauma, placing them at greater risk for SU and substance use disorders (SUDs). To ensure that these youth do not become another opioid statistic, innovative and effective prevention interventions are needed. The investigators propose to adapt and test an intervention for preventing initiation and/or escalation of opioid misuse among older JJ-involved adolescents. The target enrollment group will be youth aging out of JJ (15-18 years at study enrollment) who are transitioning to their communities after a period of detainment in a secure treatment or correctional facility. Trust-based Relational Intervention® (TBRI®; a relational, attachment-based intervention that promotes emotional regulation through interaction with responsive adults) will be adapted as a prevention intervention targeting youth at risk for SU (especially non-medical use of opioids). Safe adults (e.g., parent/guardian, extended family member) will be trained in behavior management techniques for empowering youth to appropriately express their needs, connecting them with others in pro-social ways, and correcting or reshaping undesirable behavior. The proposed Effectiveness/Implementation study will examine both the effectiveness of TBRI for preventing opioid misuse and the comparative utility of three support formats: (1) TBRI Training only, (2) TBRI Training + Structured Coaching, or (3) TBRI Training + Responsive Coaching (triggered by the youth's need/risk). A total of 360 youth/safe adult dyads will be recruited from 9 participating JJ facilities over a 3-year period, and followed for 18 months post-release (15 youth-adult dyads/year per facility). This design enables a comparison of TBRI versus Standard Reentry Practice (SRP; using a stepped-wedge design where each facility serves as its own control) plus a randomized control trial comparing 3 TBRI support formats. This study will also examine barriers and facilitators of TBRI sustainment. Ninety JJ staff (10 from each agency) will provide input annually via focus groups and surveys. TCU will work with administrators and staff at each JJ facility to implement a sustainment plan, which will include developing in-house TBRI expertise (i.e., staff training and implementation assistance). Successful completion of study aims will provide a test of the adapted intervention and will facilitate sustainment by providing training and implementation support to participating facilities.
Accumulation of amyloid-beta (Aβ) can lead to the formation of aggregates that contribute to neurodegeneration in Alzheimer's disease (AD). Despite globally reduced neural activity during AD onset, recent studies have suggested that Aβ induces hyperexcitability and seizure-like activity during the early stages of the disease that ultimately exacerbate cognitive decline. However, the underlying mechanism is unknown. Here, we reveal an Aβ-induced elevation of postsynaptic density protein 95 (PSD-95) in cultured neurons in vitro and in an in vivo AD model using APP/PS1 mice at 8 weeks of age. Elevation of PSD-95 occurs as a result of reduced ubiquitination caused by Akt-dependent phosphorylation of E3 ubiquitin ligase murine-double-minute 2 (Mdm2). The elevation of PSD-95 is consistent with the facilitation of excitatory synapses and the surface expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors induced by Aβ. Inhibition of PSD-95 corrects these Aβ-induced synaptic defects and reduces seizure activity in APP/PS1 mice. Our results demonstrate a mechanism underlying elevated seizure activity during early-stage Aβ pathology and suggest that PSD-95 could be an early biomarker and novel therapeutic target for AD.
Methods, systems, and products monitor a person's regimen for medicinal and dietary restrictions. When the person's regimen requires a liquid medication or supplement, an oral instrument is commanded to dispense a dosage of fluid. The oral instrument stores a reservoir of the fluid. If the oral instrument is a spoon, for example, the spoon may automatically dispense cough syrup or other medicine. A toothbrush, likewise, may automatically dispense mouthwash. A sensor may confirm presence of the oral instrument in the person's mouth, thus ensuring the dosage of fluid is ingested.
BACKGROUND AND AIMS: Despite advances in technology and techniques, the recurrence rate of persistent atrial fibrillation (AF) following catheter ablation remains high. The Shensong Yangxin (SSYX) capsule, a renowned traditional Chinese medicine formula, is used in the treatment of cardiac arrhythmias. This trial aimed to investigate whether the SSYX can improve clinical outcomes in patients who have undergone catheter ablation for persistent AF.
METHODS: A multi-centre, randomized, double-blind, placebo-controlled clinical trial was conducted at 66 centres in China among 920 patients with persistent AF undergoing first ablation. Participants were randomized to oral SSYX, 1.6 g (.4 g/granule) thrice daily (n = 460), or matched placebo (n = 460) for 12 months. The primary endpoint was recurrent atrial tachyarrhythmias lasting for ≥30 s following a blanking period of 3 months. Secondary endpoints included time to first documented atrial tachyarrhythmias, AF burden, cardioversion, stroke/systemic embolism, changes in echocardiographic parameters, and quality-of-life (QoL) score. Analyses were performed according to the intention-to-treat principle.
RESULTS: A total of 920 patients underwent randomization (460 assigned to SSYX group and 460 assigned to placebo group). During the follow-up of 12 months, patients assigned to SSYX had a higher event-free rate from recurrent atrial tachyarrhythmias when compared with the placebo group (12-month Kaplan-Meier event-free rate estimates, 85.5% and 77.7%, respectively; hazard ratio, .6; 95% confidence interval .4-.8; P = .001). Patients assigned to receive SSYX had a better QoL score at 12 months compared to those randomized to placebo. There was no significant difference in the incidence of serious adverse events between the two groups.
CONCLUSIONS: Treatment with SSYX following radiofrequency catheter ablation for persistent AF reduced the incidence of recurrent atrial tachyarrhythmias and led to clinically significant improvements in QoL during a 12-month follow-up in a Chinese population.
PURPOSE OF REVIEW: The objective of this review is to summarize the literature on the prevalence and diagnosis of obesity and its metabolic profile, including bone metabolism, focusing on the main inflammatory and turnover bone mediators that better characterize metabolically healthy obesity phenotype, and to summarize the therapeutic interventions for obesity with their effects on bone health.
RECENT FINDINGS: Osteoporosis and fracture risk not only increase with age and menopause but also with metabolic diseases, such as diabetes mellitus. Thus, patients with high BMI may have a higher bone fragility and fracture risk. However, some obese individuals with healthy metabolic profiles seem to be less at risk of bone fracture. Obesity has become an alarming disease with growing prevalence and multiple metabolic comorbidities, resulting in a significant burden on healthcare and increased mortality. The imbalance between increased food ingestion and decreased energy expenditure leads to pathological adipose tissue distribution and function, with increased secretion of proinflammatory markers and harmful consequences for body tissues, including bone tissue. However, some obese individuals seem to have a healthy metabolic profile and may not develop cardiometabolic disease during their lives. This healthy metabolic profile also benefits bone turnover and is associated with lower fracture risk.